The development of novel inhibitors of tumor necrosis factor-alpha (TNF-alpha) production based on substituted [5,5]-bicyclic pyrazolones

Identification of potential TNF-α inhibitors: from in silico to in vitro studies

Tumor Necrosis Factor Alpha (TNF-α) is a pleiotropic pro-inflammatory cytokine. It act as central biological regulator in critical immune functions, but its dysregulation has been linked with a number of diseases. Inhibition of TNF-α has considerable therapeutic potential for diseases such as cancer, diabetes, and especially autoimmune diseases. Despite the fact that many small molecule inhibitors have been identified against TNF-α, no orally active drug has been reported yet which demand an urgent need of a small molecule drug against TNF-α. This study focuses on the development of ligand-based selective pharmacophore model to perform virtual screening of plant origin natural product database for the identification of potential inhibitors against TNF-α. The resultant hits, identified as actives were evaluated by molecular docking studies to get insight into their potential binding interaction with the target protein. Based on pharmacophore matching, interacting residues, docking score, more affinity towards TNF-α with diverse scaffolds five compounds were selected for in vitro activity study. Experimental validation led to the identification of three chemically diverse potential compounds with the IC₅₀ 32.5 ± 4.5 µM, 6.5 ± 0.8 µM and 27.4 ± 1.7 µM, respectively.

Synthesis, spectroscopy and biological investigations of manganese(III) Schiff base complexes derived from heterocyclic β-diketone with various primary amine and 2,2'-bipyridyl

The mixed ligand mononuclear complex [Mn(bipy)(HPMFP)(OAc)]ClO(4) was synthesized by reaction of Mn(OAc)(3)·2H(2)O with HPMFP and 2,2'-bipyridyl. The corresponding Schiff base complexes were prepared by condensation of [Mn(bipy)(HPMFP)(OAc)]ClO(4) with ethylenediamine, ethanolamine and glycine (where HPMFP=1-phenyl-3methyl-4-formyl-2-pyrazolin-5one, bipy=2,2'-bipyridyl). All the compounds have been characterized by elemental analysis, magnetic susceptibility, conductometry measurements and (1)H and (13)C NMR, FT-IR, mass spectrometry. Electronic spectral and magnetic susceptibility measurements indicate square pyramidal geometry around manganese(III) ion. The thermal stabilities, activation energy E*, entropy change ΔS*, enthalpy change ΔH* and heat capacity of thermal degradation for these complexes were determined by TGA and DSC. The in vitro antibacterial and antifungal activity of four coordination compounds and ligand HPMFP were investigated. In vitro activates of Bacillus subtillis (MTCC-619), Staphylococcus aureus (MTCC-96), Escherichia coli (MTCC-722) and Klebsiella pneumonia (MTCC-109) bacteria and the fungus Candida albicans (ATCC-90028) were determined. All the compounds showed good antimicrobial activity. The antimicrobial activities increased as formation of Schiff base.

The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis

Chronic inflammatory processes are based on a sustained and tightly regulated communication network among different cells types. This network comprises extracellular mediators such as cytokines, chemokines and matrix-degrading proteases, which orchestrate the participation of cells in the chronic inflammatory process. The mirrors of this outside communication world are intracellular transcription factor pathways, which shuttle information about inflammatory stimuli to the cell nucleus. This review examines the function of one key signal transduction pathway of inflammation--the p38 mitogen-activated protein kinases (p38MAPK). The signalling pathway is considered as crucial for the induction and maintenance of chronic inflammation, and its components thus emerge as interesting molecular targets of small molecule inhibitors for controlling inflammation. This review not only summarises the current knowledge of activation, regulation and function of the p38MAPK pathway but also examines the role of this pathway in clinical disease. It gives an overview of current evidence of p38MAPK activation in inflammatory arthritis and elaborates the key molecular determinants which contribute to p38MAPK activation in joint disease.

A pyrimidine–pyrazolone nucleoside chimera with potent in vitro anti-orthopoxvirus activity

Synthetic hybridization of two privileged drug scaffolds, pyrazolone on the one hand and pyrimidine nucleoside on the other, resulted in the generation of two novel 5-substituted pyrimidine nucleosides with potent in vitro antiviral activity against two representative orthopoxviruses, vaccinia virus and cowpox virus.

The development of monocyclic pyrazolone based cytokine synthesis inhibitors

4-Aryl-5-pyrimidyl based cytokine synthesis inhibitors that contain a novel monocyclic, pyrazolone heterocyclic core are described. Many of these inhibitors showed low nanomolar activity against LPS-induced TNF-alpha production. One of the compounds (6e) was found to be efficacious in the rat iodoacetate (RIA) in vivo model of osteoarthritis. The X-ray crystal structure of a pyrazolone inhibitor cocrystallized with mutated p38 (mp38) is presented.